Altimmune, Inc. (ALT) vs Shattuck Labs, Inc. (STTK)

A side-by-side comparison of Altimmune, Inc. and Shattuck Labs, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALT vs STTK

growth of $100 · dividends reinvested · last 6y
ALT -78.4% (-22.5%/yr)STTK -66.4% (-16.6%/yr)STTK compounded faster over this window
0100200300Start $100202120222023202420252026$22$34
ALT STTK

ALT vs STTK: by the numbers

  • •STTK is the larger company ($547M vs $520M market cap).
  • •Both run net losses; STTK's is the smaller (-5256.80% vs -296000.00% net margin).
  • •Both shrank revenue over the past five years; STTK's decline was smaller (-11.25% vs -65.38% CAGR).

Metrics side by side

Valuation

MetricALTSTTK
P/S ratio16786.24546.75
P/B ratio1.102.59

Profitability

MetricALTSTTK
Gross margin100.00%-195.10%
Operating margin-230460.98%-5150.80%
Net margin-296000.00%-5256.80%
ROE-19.35%-24.90%
ROIC-19.47%-26.20%

Growth (annualized)

MetricALTSTTK
Revenue CAGR (5Y)-65.38%-11.25%
Total return CAGR (5Y)-25.30%-20.11%

Frequently asked

Which has grown faster, ALT or STTK?
Neither grew: over the past five years both shrank revenue, with STTK's decline the smaller — ALT at a -65.38% CAGR versus STTK at -11.25%.
How have ALT and STTK total returns compared?
Over the past 5 years, ALT delivered -25.30% and STTK delivered -20.11% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.